Kadry Elsaeed

534 total citations
13 papers, 364 citations indexed

About

Kadry Elsaeed is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Kadry Elsaeed has authored 13 papers receiving a total of 364 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hepatology, 11 papers in Epidemiology and 2 papers in Infectious Diseases. Recurrent topics in Kadry Elsaeed's work include Hepatitis C virus research (11 papers), Liver Disease Diagnosis and Treatment (11 papers) and Hepatitis B Virus Studies (7 papers). Kadry Elsaeed is often cited by papers focused on Hepatitis C virus research (11 papers), Liver Disease Diagnosis and Treatment (11 papers) and Hepatitis B Virus Studies (7 papers). Kadry Elsaeed collaborates with scholars based in Egypt and Philippines. Kadry Elsaeed's co-authors include Wahid Doss, Gamal Esmat, Wafaa Elakel, Imam Waked, Mohamed El‐Kassas, Magdy El‐Serafy, Mohamed Hassany, Manal H. El‐Sayed, Mohamed Shaker and Marwa Khairy and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of Hepatology and Alimentary Pharmacology & Therapeutics.

In The Last Decade

Kadry Elsaeed

11 papers receiving 357 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kadry Elsaeed Egypt	7	310	290	34	29	23	13	364
Yu Asano Japan	5	244 0.8×	228 0.8×	21 0.6×	11 0.4×	10 0.4×	7	280
Giuseppe Barbaro Italy	8	245 0.8×	261 0.9×	62 1.8×	8 0.3×	10 0.4×	9	356
G Schmutz Germany	5	216 0.7×	227 0.8×	111 3.3×	23 0.8×	3 0.1×	9	329
Osvely Méndez-Guerrero Mexico	10	121 0.4×	151 0.5×	45 1.3×	5 0.2×	6 0.3×	16	293
C. Hézode France	9	273 0.9×	251 0.9×	55 1.6×		20 0.9×	37	309
Takaaki Izumi Japan	5	102 0.3×	93 0.3×	12 0.4×	8 0.3×	10 0.4×	7	159
Toby Delahooke United Kingdom	8	195 0.6×	208 0.7×	15 0.4×		11 0.5×	15	300
Corinne Njapoum France	5	366 1.2×	404 1.4×	14 0.4×	1 0.0×	12 0.5×	6	471
S. Gordon United States	9	213 0.7×	221 0.8×	59 1.7×	1 0.0×	16 0.7×	14	295
Solange Heller Mexico	7	168 0.5×	174 0.6×	7 0.2×	11 0.4×	51 2.2×	9	252

Countries citing papers authored by Kadry Elsaeed

Since Specialization

Citations

This map shows the geographic impact of Kadry Elsaeed's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kadry Elsaeed with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kadry Elsaeed more than expected).

Fields of papers citing papers by Kadry Elsaeed

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kadry Elsaeed. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kadry Elsaeed. The network helps show where Kadry Elsaeed may publish in the future.

Co-authorship network of co-authors of Kadry Elsaeed

This figure shows the co-authorship network connecting the top 25 collaborators of Kadry Elsaeed. A scholar is included among the top collaborators of Kadry Elsaeed based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kadry Elsaeed. Kadry Elsaeed is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Elsaeed, Kadry, et al.. (2025). APEX1 as a novel diagnostic and prognostic biomarker for hepatocellular carcinoma. The Egyptian Journal of Internal Medicine. 37(1).

Elakel, Wafaa, Tamer Elbaz, Kadry Elsaeed, et al.. (2024). Diabetic patients with chronic hepatitis C virus response compared to non diabetics when treated with directly acting antiviral therapy. Arab Journal of Gastroenterology. 25(2). 118–124. 2 indexed citations

El‐Serafy, Magdy, Maissa El Raziky, Wafaa Elakel, et al.. (2023). Efficacy and safety of ombitasvir/paritaprevir/ritonavir-based therapy in HCV patients with chronic kidney disease. Arab Journal of Gastroenterology. 24(1). 29–33.

Elsaeed, Kadry, et al.. (2021). Safety and efficacy of directly acting antivirals (sofosbuvir and daclatasvir) in treatment of chronic HCV in HIV-HCV co-infected Egyptian patients. SHILAP Revista de lepidopterología. 11(1). 2 indexed citations

El‐Kassas, Mohamed, Mohamed Alboraie, Heba Omar, et al.. (2019). High success rates for the use of ombitasvir/paritaprevir/ritonavir containing regimens in treatment of naïve and experienced chronic hepatitis C genotype 4: Real world results. Journal of Medical Virology. 94(2). 667–674. 9 indexed citations

Darweesh, Samar K., Kadry Elsaeed, Heba Omar, et al.. (2019). High SVR rate following retreatment of non-sustained virological responders to sofosbuvir based anti-HCV therapies regardless of RAS testing: A real-life multicenter study. Expert Review of Gastroenterology & Hepatology. 13(9). 907–914. 6 indexed citations

El‐Kassas, Mohamed, Dalia Omran, Kadry Elsaeed, et al.. (2018). Spur-of-the-Moment Modification in National Treatment Policies Leads to a Surprising HCV Viral Suppression in All Treated Patients: Real-Life Egyptian Experience. Journal of Interferon & Cytokine Research. 38(2). 81–85. 5 indexed citations

Said, Mohamed, et al.. (2018). High prevalence of HCV (GT4)-related TSH abnormality among 13402 Egyptian patients treated with direct acting antiviral therapy. Hepatology International. 12(2). 143–148. 3 indexed citations

El‐Kassas, Mohamed, Mohamed Alboraie, Dalia Omran, et al.. (2018). An account of the real-life hepatitis C management in a single specialized viral hepatitis treatment centre in Egypt: results of treating 7042 patients with 7 different direct acting antiviral regimens. Expert Review of Gastroenterology & Hepatology. 12(12). 1265–1272. 23 indexed citations

10.

Elsharkawy, Aisha, Maissa El Raziky, Wafaa Elakel, et al.. (2017). Planning and prioritizing direct-acting antivirals treatment for HCV patients in countries with limited resources: Lessons from the Egyptian experience. Journal of Hepatology. 68(4). 691–698. 50 indexed citations

11.

Omar, Heba, Wafaa Elakel, Tamer Elbaz, et al.. (2017). Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real‐world results from 18 378 patients in Egypt. Alimentary Pharmacology & Therapeutics. 47(3). 421–431. 90 indexed citations

12.

Elakel, Wafaa, Manal H. El‐Sayed, Mohamed El‐Kassas, et al.. (2017). National treatment programme of hepatitis C in Egypt: Hepatitis C virus model of care. Journal of Viral Hepatitis. 24(4). 262–267. 140 indexed citations

13.

Elsaeed, Kadry, et al.. (2008). Paraoxonase‐1 (PON1) activity as a risk factor for atherosclerosis in chronic renal failure patients. Hemodialysis International. 12(4). 471–479. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact